Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Capital Expenditures (2023 - 2025)

Immunocore Holdings' Capital Expenditures history spans 3 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 19.64% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $4.3 million, down 16.1%, while the annual FY2025 figure was $4.3 million, 16.1% down from the prior year.
  • Capital Expenditures for Q4 2025 was $2.9 million at Immunocore Holdings, up from $748000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.6 million in Q4 2024 and bottomed at $212000.0 in Q3 2023.
  • The 3-year median for Capital Expenditures is $782500.0 (2023), against an average of $1.2 million.
  • The largest YoY upside for Capital Expenditures was 338.68% in 2024 against a maximum downside of 85.67% in 2024.
  • A 3-year view of Capital Expenditures shows it stood at $817000.0 in 2023, then skyrocketed by 338.68% to $3.6 million in 2024, then dropped by 19.64% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Capital Expenditures are $2.9 million (Q4 2025), $748000.0 (Q3 2025), and $414000.0 (Q2 2025).